Zika virus (Zika) is a disease caused by the Zika virus, which is spread to people primarily through the bite of an infected Aedes species mosquito. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis. The illness is usually mild with symptoms lasting for several days to a week after being bitten by an infected mosquito.
Future Market Insights, Dubai: The global zika virus testing market experienced a moderate incline, experiencing a CAGR of just above 2% between 2017 and 2020, being valued at a little over US$ 4 billion, as per ESOMAR-certified firm Future Market Insights (FMI) latest report on the landscape. Growth was majorly underpinned by the introduction of numerous point-of-care powerful testing approaches to facilitate timely detection of the virus.
According to FMI’s analysis, clinicians have been exhibiting a high preference towards enzyme linked immunosorbent assay (ELISA) tests. Compared to other immunoassay methods, ELISA tests are more accurate, are considered highly sensitive, specific and compare favorably with other methods used to detect substances in the body, such as radioimmune assay (RIA) tests.
Prominent players are experiencing immense growth opportunities across tropical regions, attributed to the high concentration rate of the zika virus across such regions as the Caribbean, Central America, Africa and the Asian sub-continent. Players such as EUROIMMUN have emerged at the forefront, being the first diagnostics company to provide a testing approach to detect the zika virus. Its product lines include the Anti-Zika Virus ELISA (IgA or IgG or IgM or IgAM) fully automatable test and the IIFT Arbovirus Fever Mosaic 2 (IgG or IgM) test.
To know more about this market, request a sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2913
Key Takeaways from FMI’s Zika Virus Testing Market Study
- By test type, ELISA-based zika virus testing surpassed US$ 4 billion until 2020
- By end-user, private commercial laboratories to remain primary point of contact for availing zika virus testing
- Multiple regulatory approvals for various testing approaches by the FDA to bolster US zika virus testing market growth
- Brazil to attract major zika virus testing providers amid increasing governmental initiatives to contain its spread
- Growing focus on pregnant women’s health to accelerate testing volumes in Puerto Rico
- UK to experience limited uptake amid the non-notifiable nature of the disease due to limited outbreaks
“Rising government initiatives to address possible suspected infection cases are providing a wide platform for the introduction of advanced zika virus testing approaches, providing key players a chance to expand their footprints across key geographies,” says the FMI analyst.
Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/ask-question/rep-gb-2913
Prominent zika virus testing manufacturers are reliant on offering advanced testing approaches in order to yield quicker results so as to facilitate timely treatment. Besides, key research laboratories and organizations also emphasize on expanding their testing capabilities by virtue of strategic acquisition and collaboration agreements.
In 2017, the US FDA issued an Emergency Use Authorization (EUA) to authorize the RealStar® Zika Virus RT-PCR Kit for the in vitro qualitative detection of Zika virus with specified instruments. This test is offered by Altona Diagnostics GmbH, and tests presence of the virus in human serum, EDTA plasma and/or urine.
Similarly, ARUP Laboratories offers both serology and RT-PCR tests for detecting the zika virus. The former is called the Zika Virus IgM Antibody Capture (MAC) based on the ELISA technique. In the latter case, the test is conducted by collecting patients’ blood or urine samples.
We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-2913
More Insights on the Global Zika Virus Testing Market
In its latest report, FMI offers an unbiased analysis of the global zika virus testing market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of test type (rapid IgG/IgM test and ELISA test) and end-user (hospitals & clinics, private commercial laboratories and government/publicly funded programs) across six regions (North America & Europe, Latin America, Central America, Caribbean, South East Asia and Rest of the World).
Explore FMI’s Extensive Coverage on Healthcare Domain
Hearing implant Market: Cochlear Implants to Remain Most Preferred Type of Hearing Implant; Manufacturers Focused on Launching Products with Minimal Procedural Complexity
Arthroscopy Procedure and Products Market: Knee Arthroscopy Procedure to Contribute over 50% of Arthroscopy Procedures & Products Market Share
Animal Artificial Insemination Market: Animal Artificial Insemination Market Valuation to Surpass US$ 2 Bn in 2021 Backed by Recent Advancements in Animal Science
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: email@example.com
For Media Enquiries: firstname.lastname@example.org